Onyx Liquid Embolic System (Onyx LES)
Ev3 Neurovascular · Decision date Oct 14, 2026
What did the FDA approve?
The FDA record for P030004/S039 shows an approval dated 2026-10-14 under the Normal 180 Day Track No User Fee, with the supplement reason listed as Postapproval Study Protocol. The changed item is the protocol for a Real-World Use Surveillance post-approval study for the Onyx Liquid Embolic System; the record states that this protocol was submitted to comply with conditions of approval in the earlier approval order for P030004/S035. The S039 supplement number marks it as a later supplement to the same PMA number, not a new approval of the whole system.
The decision covers the study protocol only. The record does not describe endpoints, patient population, sites, duration, or reporting requirements, and it does not report results or independent evidence of safety or clinical effectiveness. The applicant is Ev3 Neurovascular; specialty is Neurology; product code MFE, device category Agent, injectable, embolic. Those facts are absent from the supplied text and are not supplied here.
FDA approval order statement
Approval of the protocol for the Real-World Use Surveillance post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P030004/S035.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Oct 14, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030004/S039
- Regulatory pathway
- PMA supplement
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- Decision code
- APPR
- Decision date
- Oct 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, injectable, embolic.
- Applicant
- Ev3 Neurovascular
- Product code
- MFE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030004 · Original PMA
ONYX LIQUID EMBOLIC SYSTEM
P030004/S039 received
Application receipt date recorded by FDA.
P030004/S039 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030004
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ONYX LIQUID EMBOLIC SYSTEMP030004 | Ev3 Neurovascular | PMA approval | Jul 21, 2005 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ev3 Neurovascular
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9775 Toledo Way, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030004/S039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records